Identificador persistente para citar o vincular este elemento:
http://hdl.handle.net/10553/52057
Campo DC | Valor | idioma |
---|---|---|
dc.contributor.author | Wägner, Ana M. | en_US |
dc.contributor.author | Pérez, Antonio | en_US |
dc.contributor.author | Calvo, Fernando | en_US |
dc.contributor.author | Bonet, Rosa | en_US |
dc.contributor.author | Castellvi, Agustina | en_US |
dc.contributor.author | Ordóñez, Jordi | en_US |
dc.date.accessioned | 2018-11-25T17:04:53Z | - |
dc.date.available | 2018-11-25T17:04:53Z | - |
dc.date.issued | 1999 | en_US |
dc.identifier.issn | 0149-5992 | en_US |
dc.identifier.uri | http://hdl.handle.net/10553/52057 | - |
dc.description.abstract | Objective: Apolipoprotein(B) [apo(B)] reflects the total mass of atherogenic particles (VLDL, IDL, and LDL), and its increase is associated with cardiovascular disease independently of LDL cholesterol (LDLc) levels. Apo(B) determination has been recently standardized, but attention to regional reference limits is advisable. Our aim was to analyze the frequency of dyslipidemic phenotypes, including those dependent on increased apo(B) in normocholesterolemic type 2 diabetic patients. Research design and methods: A total of 100 consecutively seen type 2 diabetic patients (63 men, 37 women; aged 59 +/- 11 years) were included, after excluding those on lipid-lowering therapy. Apo(B) cutoff (1.1 g/l) was obtained from a group of normolipidemic (47 men, 21 women) control subjects, and LDLc, triglycerides, and HDL cholesterol (HDLc) cutoff points were those from the National Cholesterol Education Program guidelines. LDLc levels were obtained by ultracentrifugation if triglyceride levels were > 3.45 mmol/l; otherwise, they were calculated (Friedwald). Apo(B) levels were measured by immunoturbidimetry. Results: Normocholesterolemia (LDLc < 4.13 mmol/l) appeared in 75 of the 100 patients, of whom 55 were normo- and 20 hypertriglyceridemic. Hyperapolipoprotein(B) [hyperapo(B)] was the most frequent lipid disorder, present in 34 (45%) of the normocholesterolemic patients (22 normo- and 12 hypertriglyceridemic). Low HDLc levels were more prevalent (53%) in patients with hyperapo(B) than in the rest (24%). Conclusions: Hyperapo(B) was found in almost half of the normocholesterolemic type 2 diabetic patients and was frequently associated with low HDLc levels and hypertriglyceridemia. Thus, given its independent association with cardiovascular disease and that it identifies high-risk phenotypes in normocholesterolemic diabetic patients apo(B) should be used to evaluate the lipidic pattern of these patients. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Diabetes Care | en_US |
dc.source | Diabetes Care[ISSN 0149-5992],v. 22(5), p. 812-817 (Mayo 1999) | en_US |
dc.subject | 32 Ciencias médicas | en_US |
dc.subject | 320502 Endocrinología | en_US |
dc.subject.other | Apolipoprotein (B) | en_US |
dc.subject.other | LDL cholesterol | en_US |
dc.subject.other | Triglycerides | en_US |
dc.subject.other | Normocholesterolemia | en_US |
dc.title | Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients | en_US |
dc.type | info:eu-repo/semantics/article | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.2337/diacare.22.5.812 | en_US |
dc.identifier.scopus | 0345711503 | - |
dc.contributor.authorscopusid | 7401456520 | - |
dc.contributor.authorscopusid | 7402509742 | - |
dc.contributor.authorscopusid | 7101900838 | - |
dc.contributor.authorscopusid | 6701846436 | - |
dc.contributor.authorscopusid | 6701668294 | - |
dc.contributor.authorscopusid | 7005297613 | - |
dc.description.lastpage | 817 | en_US |
dc.description.firstpage | 812 | en_US |
dc.relation.volume | 22 | en_US |
dc.investigacion | Ciencias de la Salud | en_US |
dc.type2 | Artículo | en_US |
dc.description.numberofpages | 6 | en_US |
dc.utils.revision | Sí | en_US |
dc.date.coverdate | Mayo 1999 | en_US |
dc.identifier.ulpgc | Sí | en_US |
dc.contributor.buulpgc | BU-MED | en_US |
dc.description.jcr | 5,076 | - |
dc.description.jcrq | Q1 | - |
dc.description.scie | SCIE | - |
item.grantfulltext | none | - |
item.fulltext | Sin texto completo | - |
crisitem.author.dept | GIR IUIBS: Diabetes y endocrinología aplicada | - |
crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.dept | Departamento de Ciencias Médicas y Quirúrgicas | - |
crisitem.author.orcid | 0000-0002-7663-9308 | - |
crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.fullName | Wägner, Anna Maria Claudia | - |
Colección: | Artículos |
Citas SCOPUSTM
66
actualizado el 17-nov-2024
Citas de WEB OF SCIENCETM
Citations
56
actualizado el 17-nov-2024
Visitas
63
actualizado el 21-sep-2024
Google ScholarTM
Verifica
Altmetric
Comparte
Exporta metadatos
Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.